UVA Light Device to Treat COVID-19
Respiratory Application of a Novel Ultraviolet Light Delivery Device for Patients Infected With COVID-19: A Pilot Study
1 other identifier
interventional
5
1 country
1
Brief Summary
This pilot study will assess the safety and effectiveness of UV light treatment in hospitalized patients with COVID-19.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Oct 2020
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 28, 2020
CompletedFirst Posted
Study publicly available on registry
October 1, 2020
CompletedStudy Start
First participant enrolled
October 30, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 28, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 28, 2020
CompletedResults Posted
Study results publicly available
January 18, 2022
CompletedJanuary 9, 2025
December 1, 2024
2 months
September 28, 2020
September 22, 2021
December 17, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Negative Change in Viral Load
Change of viral load in upper airway in patients admitted to hospital for COVID-19
5 days
Secondary Outcomes (7)
Change in Bacterial Load
5 days
Ventilated Associated Pneumonia
1 month
Days to Extubation
1 month
Days to Discharge
1 month
Change in C-reactive Protein
5 days
- +2 more secondary outcomes
Study Arms (1)
Endotracheal UV Light
EXPERIMENTALMechanically ventilated patients who will receive UV Light therapy
Interventions
UV light therapy administered while patient is mechanically ventilated
Eligibility Criteria
You may qualify if:
- Confirmed positive test result for SARS-CoV-2
- Mechanically ventilated
- Endotracheal tube inner diameter of at least 7.5 mm
You may not qualify if:
- Unable to provide informed consent (or surrogate)
- Enrolled in a therapeutic clinical trial for same condition that does not allow recruitment in other trials
- Pregnant women
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cedars-Sinai Medical Centerlead
- Aytu BioPharma, Inc.collaborator
Study Sites (1)
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
Related Publications (1)
Rezaie A, Melmed GY, Leite G, Mathur R, Takakura W, Pedraza I, Lewis M, Murthy R, Chaux G, Pimentel M. Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study. Adv Ther. 2021 Aug;38(8):4556-4568. doi: 10.1007/s12325-021-01830-7. Epub 2021 Jun 26.
PMID: 34173969RESULT
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Melissa Hampton
- Organization
- Cedars-Sinai
Study Officials
- PRINCIPAL INVESTIGATOR
George Chaux, MD
Cedars-Sinai Medical Center
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Medical Director, Lung Transplant Program
Study Record Dates
First Submitted
September 28, 2020
First Posted
October 1, 2020
Study Start
October 30, 2020
Primary Completion
December 28, 2020
Study Completion
December 28, 2020
Last Updated
January 9, 2025
Results First Posted
January 18, 2022
Record last verified: 2024-12
Data Sharing
- IPD Sharing
- Will not share